Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDNL vs ECG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECG Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

ECG Overall Winner 6-Pillar Tally: CDNL 0 – 6 ECG Matrix Metrics: CDNL 0 – 10 ECG

As of Nov 20, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over CDNL (CDNL) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDNL carries a Unified Composite Score of 44.2/100 (HOLD) at $4.75 (N/M Forward P/E, N/A operating margin), whereas ECG carries 50.0/100 (HOLD) at $76.59 (10.8x Forward P/E, 8.2% operating margin).

  • Technical & Structure Timing Caution: CDNL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9); meanwhile ECG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDNL vs ECG
CDNL US Equity
CDNL
Institutional Equity
$4.75
-8.4% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.65β · 238% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 45.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.9%), weak momentum, RSI 23
RSI-14: 22.9 · SMA20: $11.67 · SMA50: $19.54
ECG NYSE Head-to-Head Winner
Everus Construction Group, Inc.
Operative Builders
$76.59
-8.66% 1D
Market Cap $4.3B
TTM Revenue $4.66B
Forward P/E 10.8x
Beta / 30D Vol 2.17β · 127% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 73.0 Fund 64.0 Flow 55.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.7%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $90.35 · SMA50: $105.19

6-Pillar Scorecard Institutional Category Breakdown (CDNL 0 – 6 ECG)

Columns: Metric · CDNL · ECG
1. Valuation Multiples ECG
Forward P/E N/M 10.8x
Trailing P/E N/M 15.1x
PEG Ratio N/M N/M
EV / Revenue N/M 1.0x
2. Growth & Scale ECG
Revenue Growth (YoY) N/A +40.3%
Earnings Growth (YoY) N/A +61.3%
TTM Revenue (USD) N/A $4.66B
Market Cap N/A $4.3B
3. Profitability & Quality ECG
Gross Margin N/A 13.6%
Operating Margin N/A 8.2%
Net Profit Margin N/A 6.2%
Return on Equity (ROE) N/A 40.3%
4. Balance Sheet & Cash Flow ECG
Cash Generation (TTM) N/A $237M
Cash Flow Margin N/A 5.1%
Net Cash / Leverage N/A ROE $439M Net Debt (0.81x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ECG
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 69.2% (6th %ile)
Put/Call OI Skew N/A 8.85x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ECG
OpEx & R&D Intensity N/A 5.4% of Rev ($252M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Institutional Equity Operator Engineering & Construction Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDNL (0) vs ECG (10)
Institutional Metric CDNL ECG Criterion Row Edge
Market Capitalization
Scale
N/A $4.3B Larger Scale ECG
Trailing P/E Ratio
Valuation
N/M 15.1x Lower Multiple ECG
Forward P/E Ratio
Valuation
N/M 10.8x Lower Multiple ECG
Revenue Growth (YoY)
Growth
N/A +40.3% Higher Growth ECG
Operating Margin (TTM)
Profitability
N/A 8.2% Higher Margin ECG
Net Profit Margin
Profitability
N/A 6.2% Higher Margin ECG
Return on Equity (ROE)
Capital Efficiency
N/A 40.3% Higher ROE ECG
52-Week Range Position
Momentum
0% ($5–$96) 6% ($70–$172) Stronger Trend ECG
Beta / 30D Volatility
Risk Regime
2.65β · 238% Vol 2.17β · 127% Vol Lower Realized Risk ECG
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 50.0 / 100 (HOLD) Higher Composite ECG
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 13.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $237M ($439M Net Debt (0.81x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ECG +44.26 pp
CDNL: -65.34% · ECG: -21.08%
3M Horizon ECG +52.05 pp
CDNL: -88.49% · ECG: -36.44%
6M Horizon ECG +41.81 pp
CDNL: -90.29% · ECG: -48.48%
1Y Horizon ECG +61.76 pp
CDNL: -79.57% · ECG: -17.81%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDNL vs ECG. Trailing 12-month operating profitability (CDNL N/A vs ECG 8.2%) and valuation multiples (CDNL N/M vs ECG 10.8x Forward P/E) are benchmarked directly in Pillar 4 below.

CDNL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ECG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.66B
Gross Margin13.6%
Op. Margin8.2%
ROE / Fwd P/E40.3% · 10.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDNL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDNL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ECG BREAKDOWN
138d in phase · OBV NEUTRAL
Current IV 69.2%
IV Percentile 6th %ile
Put/Call OI Skew 8.85x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ECG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDNL Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ECG Moat Profile High-Margin Pricing Power Moat
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $4.3B market capitalization and 8.2% operating margin.
OpEx & R&D Reinvestment 5.4% of Rev ($252M)
90D Engineering Disclosures 0 Published

Investor FAQ CDNL vs ECG Key Questions & Quantitative Answers

As of Nov 20, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over CDNL (CDNL) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDNL carries a Unified Composite Score of 44.2/100 (HOLD) at $4.75 (N/M Forward P/E, N/A operating margin), whereas ECG carries 50.0/100 (HOLD) at $76.59 (10.8x Forward P/E, 8.2% operating margin). Technical & Structure Timing Caution: CDNL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9); meanwhile ECG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECG leads the Growth & Scale pillar: CDNL posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ECG at +40.3% YoY revenue growth and +61.3% YoY earnings growth on $4.66B TTM revenue (13.6% gross margin, 8.2% operating margin). On trailing 12-month operating scale, CDNL generates N/A in USD-normalized revenue versus $4.66B for ECG. In operating R&D and SG&A reinvestment, CDNL deploys N/A (0 90-day corporate R&D disclosures) versus 5.4% of Rev ($252M) (0 disclosures) for ECG.

ECG screens cheaper on headline valuation multiples. CDNL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ECG trades at 10.8x Forward P/E, 15.1x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (5.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDNL (N/A ROE) versus ECG (40.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CDNL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.65β · 238% Vol realized risk). By comparison, ECG carries 69.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 8.85x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.17β · 127% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.